Last $0.17 USD
Change Today -0.0059 / -3.31%
Volume 326.7K
MYRX On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

myrexis inc (MYRX) Snapshot

Open
$0.17
Previous Close
$0.18
Day High
$0.18
Day Low
$0.16
52 Week High
10/25/13 - $0.24
52 Week Low
07/23/13 - $0.07
Market Cap
5.9M
Average Volume 10 Days
54.3K
EPS TTM
$-0.43
Shares Outstanding
34.5M
EX-Date
02/19/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYREXIS INC (MYRX)

Related News

No related news articles were found.

myrexis inc (MYRX) Related Businessweek News

No Related Businessweek News Found

myrexis inc (MYRX) Details

Myrexis, Inc., a biopharmaceutical company, focuses on identifying, evaluating, and acquiring commercial-stage biopharmaceutical assets. The company intends to acquire one or more commercial-stage biopharmaceutical assets. As of February 2012, it suspended development activities of all its preclinical and clinical programs in oncology and autoimmune diseases, and continues to pursue business development opportunities for each of its programs. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.

1 Employees
Last Reported Date: 07/17/13

myrexis inc (MYRX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.0
Compensation as of Fiscal Year 2013.

myrexis inc (MYRX) Key Developments

Myrexis Files Form 15

Myrexis, Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.01 par value per share under the Securities Exchange Act of 1934, as amended.

Myrexis, Inc. Announces Board Changes

Effective April 18, 2013, Myrexis, Inc.'s Board of Directors appointed directors to Board committees and designated the chairman of each committee as Michael C. Pearce and Steven D. Scheiwe (Chair) to Audit Committee; Michael C. Pearce (Chair) and Steven D. Scheiwe to Compensation Committee; and Michael C. Pearce (Chair) and Steven D. Scheiwe to Nominating and Corporate Governance Committee.

Myrexis, Inc. Recommends Amendments to Certificate of Incorporation

Myrexis, Inc. at its AGM to be held on April 26, 2013, recommended to approve an amendment to the company’s Certificate of Incorporation to restrict certain transfers of common stock in order to preserve the tax treatment of the company's net operating losses and other tax benefits.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYRX:US $0.17 USD -0.0059

MYRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYRX.
View Industry Companies
 

Industry Analysis

MYRX

Industry Average

Valuation MYRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYREXIS INC, please visit www.myrexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.